



Walsh, M. A., Turner, C., Timothy, K. W., Seller, N., Hares, D. L., James, A. F., ... Mcleod, K. (2018). A multicentre study of patients with Timothy syndrome. *EP-Europace*, 20(2), 377-385. [euw433].
<https://doi.org/10.1093/europace/euw433>

Peer reviewed version

Link to published version (if available):
[10.1093/europace/euw433](https://doi.org/10.1093/europace/euw433)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford Academic at <https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euw433/3089666>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/pure/about/ebr-terms>

A Multicenter Study of Patients with Timothy Syndrome

Mark A. Walsh, MD ^{1,2}, Christian Turner, MD ^{3,4}, Katherine W. Timothy, BS ⁵, Neil Seller, MD ³, Dominic L. Hares, MD ⁶, Andrew F. James, DPhil ⁷, Jules C. Hancox, FBPhS, FRSB ⁷, Orhan Uzun, MD ⁸, Dean Boyce, MD ⁹, Alan. G. Stuart, MD ^{1,2}, Paul Brennan, MD ¹⁰, Caroline Sarton, BS ¹¹, Karen McGuire, PhD ¹¹, Ruth A. Newbury-Ecob, MD ¹², Karen Mcleod, MD ¹³

¹ Bristol Royal Hospital for Children, ² Bristol Heart Institute, University Hospital Bristol, Bristol, United Kingdom

³ Department of Congenital Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom

⁴ Children's Hospital at Westmead, Sydney, Australia

⁵ Katherine W Timothy, Clinical Coordinator (retired), Children's Hospital Boston Harvard Medical School, Boston, Massachusetts

⁶ Department of Cardiology, The Yorkshire Heart Centre, Leeds General Infirmary, Leeds, United Kingdom

⁷ School of Physiology, Pharmacology and Neuroscience Cardiovascular Research Laboratories, University of Bristol

⁸ Department of Cardiology, University Hospital Wales, Cardiff

⁹ Department of Plastic Surgery, University Hospital Wales, Cardiff

¹⁰ Department of Clinical Genetics, Freeman Hospital, Newcastle upon Tyne, United Kingdom

¹¹ Oxford Medical Genetics Laboratories, Cardiac Service, Oxford University Hospitals NHS Trust, The Churchill Hospital, Oxford

¹² Department of Clinical Genetics, University Hospital Bristol, Bristol, United Kingdom

1
2
3
4
5
6

¹³ Department of Cardiology, Royal Hospital for Sick Children, Glasgow, United Kingdom

1 *Correspondence: Mark Walsh, Bristol Royal Hospital for Children, Upper Maudlin*
2 *Street, Bristol, BS2 8BJ*

3

4 *Email: mark.walsh@UH Bristol.nhs.uk*

5

6 *Phone: 0117 3428852*

7

8

9 *None of the authors have any conflict of interest to declare.*

10

11 *Word count:*

12

13 *Tables – 2*

14 *Figures – 6*

1 **Keywords**
2
3 Timothy Syndrome,
4
5 Long QT
6
7 Pediatrics,
8
9 Cardiac arrest,
10
11 Defibrillator

1 **Abbreviations**

2 Timothy Syndrome: TS

3 Automated External Defibrillator: AED

4 Implantable Cardiac Defibrillator: ICD

1 **Abstract**

2 **Background** - Timothy syndrome (TS) is an extremely rare multisystem disorder
3 characterized by marked QT prolongation, syndactyly, seizures, behavioral
4 abnormalities, immunodeficiency and hypoglycemia. There is a propensity to
5 develop malignant arrhythmias at a young age, with many patients requiring
6 defibrillator implantation.

7 **Methods** - This multicenter study looks study looks at all patients diagnosed with
8 TS in the United Kingdom over a 24-year period. Fifteen centers in the British
9 Congenital Arrhythmia Group network were contacted to partake in the study.

10 **Results** - Six patients with Timothy syndrome were identified over a 24-year period
11 (4 boys and 2 girls). Five out of six were confirmed to have a *CACNA1C* mutation
12 (p.Gly406Arg) and the other patient was diagnosed clinically. Early presentation
13 with heart block, due to QT prolongation was frequently seen. Four are still alive,
14 two of these have a pacemaker and two have undergone defibrillator implantation.
15 Five out of six patients have had a documented cardiac arrest with three occurring
16 under general anesthesia. Two patients suffered a cardiac arrest while in hospital
17 and resuscitation was unsuccessful, despite immediate access to a defibrillator.
18 Surviving patients seem to have mild developmental delay and learning difficulties.

19 **Conclusion** - Timothy syndrome is a rare disorder with a high attrition rate if
20 undiagnosed. Perioperative cardiac arrests are common and not always amenable to
21 resuscitation. Longer-term survival is possible, however patients invariably require
22 pacemaker or defibrillator implantation.

23

1 Introduction

2 Timothy syndrome (TS) is an extremely rare multisystem disorder caused by a *de*
3 *novo* mutation in the alternatively spliced exon 8A affecting *CACNA1C*, the gene
4 encoding the Cav1.2 calcium channel (p.Gly406Arg).¹⁻³ The Cav1.2 channel is critical
5 for the plateau phase of the cardiac action potential, cellular excitability, excitation-
6 contraction coupling, and regulation of gene expression.^{4, 5} In TS the mutation
7 causes impaired inactivation of open-state voltage-dependent L-type calcium
8 channels, which results in a relatively sustained inward Ca²⁺ current.⁶ It is
9 characterized by marked QT prolongation, syndactyly, immune deficiency, seizures,
10 congenital heart defects, cognitive abnormalities, learning difficulties and
11 intermittent hypoglycemia.^{2, 7} Timothy syndrome type 2 (TS2) is used to describe
12 patients with the above phenotype but without syndactyly. Mutations in exon 8,
13 rather than exon8A (p.Gly402Ser and p.Gly406Arg) have been described in TS2;
14 differential expression of exon 8 / 8A in the heart and brain are thought to account
15 for the different phenotypes.³ It is a remarkably genetically homogenous disorder,
16 with most reported phenotypes accounted for by these two genotypes.³

17

18 From the limited case reports available, both TS1 and TS2 usually present at a
19 young age. The two most common modes of presentation are heart block as a result
20 of QT prolongation and cardiac arrest.⁸ General anesthesia appears to be a
21 particularly vulnerable time for these patients, with some undiagnosed patients
22 presenting with a cardiac arrest during syndactyly surgery.⁹ Without treatment
23 survival is unlikely due to the propensity for malignant arrhythmias. With improved

1 understanding how antiarrhythmic medications affect the heart in TS, and better
2 pacemaker / defibrillator therapies, survival into young adulthood is also possible.³
3 In this study we looked at all patients who were diagnosed with TS1 and TS2 in the
4 United Kingdom over a 24-year period, which represents the only multi-center
5 published to date.
6

1 **Methods**

2

3 This is a multicenter study conducted on behalf of the British Congenital Arrhythmia
4 group (BCAG), which is a network of all hospitals managing paediatric arrhythmias
5 and inherited cardiac conditions in the United Kingdom. The network consists of 15
6 centers, 12 of which perform paediatric cardiac surgery / interventions, and 3 of
7 which are non-surgical. All centers have a paediatric cardiologist with a specialist
8 interest in inherited cardiac conditions. The study was coordinated through Bristol
9 Royal Hospital for Children. Research and ethics approval was obtained prior to
10 commencing the study. Representatives for all centers were contacted to contribute
11 cases. Any patients who were either born in, or currently reside in the United
12 Kingdom were eligible for inclusion in the study.

13

14

15 **Patient Demographics**

16 Basic demographic details were collected from a combination of cases notes review,
17 discussion with physicians, and discussions with TS patients' families. In particular
18 we were interested in the antenatal history, age at presentation, the presence of
19 heart block, QTc at presentation, and medications. We collected data on
20 interventions such as placement of pacemakers, ICDs, the timing of these
21 interventions, and occurrence of appropriate / inappropriate shocks. Also, we
22 looked at any non-arrhythmia related episodes of cardiovascular compromise.

23

24

1 **Genetics**

2 Most genetic testing inherited channelopathies are currently performed at Oxford
3 Genetics Laboratories in the United Kingdom. We reviewed the database at this
4 laboratory and there were no additional cases found other than the ones provided
5 by the BCAG members. Other genetics laboratories were contacted to get specific
6 details on mutations and to obtain illustrations. Given the rarity of this disorder and
7 the high attrition rate, we thought that patients should be included if there was a
8 strong index of suspicion, in the absence of genetic confirmation of the condition.
9 Information was also requested on immediate family members, although genetic
10 testing was not performed on any of them.

11

12

13 Exon 8 of the *CACNA1C* gene (accession sequence NM_001167625.1) was amplified
14 by PCR from genomic DNA (as supplied) using a readymade mastermix, KAPA2G
15 Fast HS Readymix, supplied by Kappa Biosystems. Bidirectional fluorescent dideoxy
16 sequencing was performed using Applied Biosystems Big Dye Terminator v3.1 kit
17 followed by capillary electrophoresis on the Applied Biosystems 3730. Analysis
18 involved manual interrogation at nucleotide position c.1216. Variant description is
19 according to Human Genome Variation Society (HGVS) nomenclature. Internal
20 quality control samples were run for each test, including negative (water blank),
21 positive (DNA from the proband) and normal (previously assigned normal
22 sequencing control). The test was undertaken using two non-overlapping primer
23 sets so as to eliminate the possibility of allele drop out due to their being a
24 polymorphism in the primer binding site.

1 Results

2 All 15 centers in the BCAG network were contacted and the response rate was
3 100%. A total of six patients with TS were identified at five centers from January
4 1992 to April 2016; ten centers confirmed that they didn't have any cases. During
5 this time period in the United Kingdom there were approximately 16 million live
6 births, giving an approximate incidence of 1.5 in 10^8 births per year.¹⁰ In total there
7 were 4 boys and 2 girls. Two of the patients were monozygous twins (both male). At
8 the time of writing 4 out of 6 patients are still alive (table 1). Of the patients that are
9 alive, two have pacemakers and two have had a defibrillator placed (table 2). A
10 summary of the clinical course of all six patients is outlined below. There was no
11 significant family history of sudden death in any of the patients. We were able to
12 ascertain that 4 out of 5 parents of index cases were assessed clinically and did not
13 demonstrate any clinical phenotypical features of TS. None of the parents of index
14 cases underwent genetic testing.

15

16

1 **Patient # 1**

2 This patient was delivered at 28 weeks by emergency caesarian section (weight 980
3 grams) for fetal bradycardia. The baby initially required ventilation for respiratory
4 distress syndrome and remained intubated for four weeks after delivery. There was
5 marked prolongation of the QT interval (QTc: 600 msec), which was causing 2:1
6 heart block with hemodynamic instability. An attempt was made to slow the heart
7 rate with intravenous propranolol, however propranolol administration caused
8 further prolongation of the QT interval (Figure 1). A low dose of isoproterenol (0.01
9 mcg/kg/min) was commenced which resulted in some improvement. Mexiletine (4
10 mg/kg, Q8 hourly) was added at four weeks of age which resulted in further
11 improvement, however intermittent 2:1 block was still present (Figure 2). Genetic
12 testing confirmed the presence of a *CACNA1C* mutation. At eight weeks of age during
13 induction of anesthesia for a Hickman line, the patient had an episode of ventricular
14 fibrillation that required cardioversion. The isoproterenol infusion was continued at
15 rates of 50 – 250 ng/kg/min until an epicardial pacemaker could be undertaken;
16 this was performed at 12 weeks of age at a weight of 2.2 kg. Propranolol 1 mg / kg
17 was also commenced, in addition to Mexiletine, once satisfactory pacing was
18 achieved.

19

20 The patient was discharged after a hospital stay of three months. At 12 months of
21 age she was admitted to hospital with gastroenteritis and suffered another cardiac
22 arrest. Cardiopulmonary resuscitation was performed immediately and an
23 automated external defibrillator (AED) was attached; the rhythm was judged not to

1 require cardioversion. The patient recovered after five minutes of resuscitation.
2 There was mild hyperkalemia at the time of the cardiac arrest (6.7 mmol/L) and
3 blood glucose was confirmed to be normal. At 15 months of age one of the epicardial
4 leads became fractured. A transvenous pacemaker was placed without any
5 complications. The patient's current medications consist of mexiletine and
6 propranolol. Regular Holter monitors have not demonstrated any arrhythmias. She
7 is currently managed with a pacemaker and an AED, however consideration will be
8 given to upgrade to an ICD when she is of sufficient size.

9

1 **Patient #2**

2

3 Patient #2 was born at 30 weeks gestation (weight 1.5 kg) due to premature labor.

4 The patient was noted to be in heart block on fetal echocardiograms. There was

5 prolongation of the QT interval at birth (600 msec) with 2:1 heart block. The patient

6 was noted to have syndactyly of the index, middle and ring fingers on both hands.

7 Genetic testing confirmed the presence of a *CACNA1C* mutation. There was a patent

8 ductus arteriosus and a ventricular septal defect which both closed spontaneously.

9 The patient was maintained on atenolol initially and subsequently nadolol. A

10 pacemaker was placed at two years of age. An episode of ventricular fibrillation

11 occurred during induction of anesthesia that was treated with DC cardioversion. The

12 patient was noted to have seizure activity on transfer to the ward afterwards,

13 however made a good recovery and was discharged. During a respite hospice

14 admission, he had another cardiac arrest that was cardioverted successfully by an

15 AED. He was subsequently transferred to hospital and made a good recovery,

16 although he did have some ongoing seizures. Unexpectedly, he had a sudden

17 unprovoked cardiac arrest while still in hospital. Immediate cardiopulmonary

18 resuscitation was commenced. His initial rhythm was pulseless electrical activity,

19 which was followed soon afterwards by asystole. His pacemaker was functioning

20 appropriately at the time and pacing at its lower limit. Blood glucose was checked

21 around the time of cardiac arrest, which was normal.

22

1 **Patient #3**

2

3 This patient is likely one of the oldest patients alive with TS (24 years old). She was
4 born at term with a weight of 3 kg. She had an out of hospital cardiac arrest at one
5 year of age. She was successfully cardioverted from ventricular fibrillation and
6 transferred to hospital. She had a QT interval of 600 msec, however it was not clear
7 whether this was related to the cardiac arrest. There was no evidence of
8 atrioventricular block. Other than a patent ductus arteriosus she had a structurally
9 normal heart. She never had any seizures. She was treated with atenolol 1 mg / kg
10 twice daily. Four years later she had another out-of-hospital cardiac arrest that
11 resulted in a neurological injury. An epicardial defibrillator was placed at 5 years of
12 age using pericardial patches and an endocardial pace-sense lead. She had an
13 appropriate shock from this device at 8 years of age. Genetic testing confirmed the
14 presence of a *CACNA1C* mutation. She had had multiple device changes and lead
15 extractions. Currently she is living independently; she has mild learning difficulties
16 and mild residual weakness as a result of her previous neurological injury.

17

1 **Patient #4**

2 A 13-month-old boy was admitted for bilateral syndactyly release. He had soft
3 systolic heart murmur, however it is not clear whether an echocardiogram was
4 performed. There was syndactyly of the little and ring fingers. Anesthesia was
5 induced and maintained with sevoflurane. One hour into the procedure, it was
6 noticed that the patient was in ventricular bigeminy and T-wave alternans; all other
7 parameters remained unchanged so the operation continued. One hour later, the
8 patient had a cardiac arrest due to ventricular fibrillation, which was successfully
9 cardioverted. Two further cardioversions were performed due to a reoccurrence of
10 ventricular fibrillation. A narrow complex tachycardia followed, with good cardiac
11 output. Subsequently a bradycardia ensued with no palpable pulse. Further
12 attempts at resuscitation were unsuccessful and 75 minutes after the initial arrest,
13 resuscitation was discontinued. The post mortem demonstrated a patent ductus
14 arteriosus, a myocardial bridge over the right coronary artery, myocardial fibrosis
15 and endocardial fibroelastosis. Subsequent examination of the ECG strip confirmed
16 the presence of a prolonged QT interval, which was unknown to the treating
17 clinicians. Genetic testing was not performed on this patient

18

19

20

1 **Patient #5**

2 Twin I of monozygous twins, long QT syndrome was first suspected when transient
3 2:1 atrioventricular block was noticed as a neonate. Serial ECGs showed persistent
4 QTc prolongation of up to 554 ms and, despite the absence of symptoms, he was
5 started on treatment with nadolol 1 mg/kg/day at the age of two years. An episode
6 of syncope at five years of age prompted implantation of a loop recorder. On
7 induction of anesthesia for this procedure he developed torsade de pointes,
8 followed by sinus rhythm with T wave alternans (figure 5). A further episode of
9 torsade de pointes was then documented, and an ICD was subsequently implanted
10 for recurrent syncope despite adequate beta blockade. The ICD has delivered
11 appropriate therapy on several occasions although there has been only one
12 recurrence of arrhythmia (precipitated by a fire alarm at school) since the nadolol
13 administration was changed to 0.5 mg/kg twice daily. Twin I's QTc intervals have
14 ranged from 522 to 554 ms. His other problems have included an inguinal hernia,
15 congenital dysplasia of the hip, strabismus requiring glasses and otitis media with
16 effusions, managed with grommets. His joints are hypermobile, and he wears splints
17 to support his ankles and feet. He has global developmental delay, with delay in
18 gross motor, fine motor skills, with a limited vocabulary, communicating primarily
19 by signing. At a recent assessment, he was on the 3rd centile for height (just below
20 the lower limit of his parental range), and on the 25th centile for weight. At birth he
21 was between the 50th and 75th centile for weight. Twin I does not have congenital
22 heart disease. He does not have syndactyly. He has bilateral epicanthic folds but
23 otherwise no facial dysmorphism.

1 Subsequent molecular analysis demonstrated the pathogenic *CACNA1C* gene
2 mutation c.1216G>A (pGly406Arg) in mosaic form in both twins. This mutation was
3 absent, however, from both parents, suggesting that the mutation arose as a *de novo*
4 event. Testing of DNA extracted from buccal smear samples confirmed that the
5 mutation was present in both twins in mosaic form (Figure 4).

6

7

1 **Patient #6**

2 Twin II presented with cyanosis and was diagnosed with pulmonary atresia and
3 ventricular septal defect. This was initially palliated with arterial shunts before
4 repair with a Rastelli procedure at four years of age. His ECGs also showed a long
5 QTc interval (range 493 to 555 ms), and he has been treated with nadolol since the
6 age of two years. Other than transient 2:1 AV block he has not had overt arrhythmia.
7 Other medical problems consisted of bilateral inguinal hernias and undescended
8 testes requiring repair. Following one of the cardiac surgical procedures, he
9 developed a Klebsiella urinary tract infection. He subsequently also developed
10 Morexella endocarditis. Failure-to-thrive has recently been treated with growth
11 hormone. At two years of age, he was found to be intolerant to lactose and soya.
12 Following exclusion of these, his slow growth improved. Whilst twin II does not
13 have strabismus, he has previously had abnormal eye movements. Investigation
14 with electroencephalogram was normal. He weighed 1599 g at birth (10th centile).
15 At a recent assessment, he was below the 3rd centile for height (3.85 STD below the
16 mean) and weight just below the 3rd centile. He has hypermobile joints. Like his
17 brother, twin II also has global development delay, particularly in the areas of
18 speech and language, but also in fine and gross motor skills. He does not have
19 syndactyly; he also has bilateral epicanthic folds but otherwise no facial
20 dysmorphism. He has postural plagiocephaly. He currently has a single chamber
21 pacemaker, however has not required placement of an ICD.

22

1 Discussion

2 This is the first multicenter study looking at outcomes for patients with TS. All
3 patients in the series had the same mutation (p.Gly406Arg) affecting the *CACNA1C*
4 gene. Early presentation is common and pacing / defibrillator placement is usually
5 required. Patients are at high risk of ventricular arrhythmias, particularly during
6 general anesthesia, indeed this was the initial presentation in one case. It is clearly a
7 complex multisystem disorder, some of the facets of which are poorly understood:
8 this is evident by the fact that 2 patients died in hospital despite good apparent
9 resuscitation and appropriate cardioversion. Other patients have had successful
10 cardioversion following cardiac arrest, demonstrating that defibrillator therapy can
11 be life saving. Neurological impairments are frequent, most commonly seizures, as
12 are mild learning difficulties. This study also demonstrates that with appropriate
13 medical and device therapy, survival into adulthood is possible.

14

15 As with other reports, this study demonstrates the genetic homogeneity of TS with
16 all phenotypes resulting from the same mutation (p.Gly406Arg), exon 8A for TS1
17 and exon 8 for TS2. It is a missense mutation in the pore-forming region of the
18 Cav1.2 channel that is highly conserved across various species.^{3, 11} The other
19 mutation described only in TS2 is a missense mutation, (p.Gly402Ser / exon 8) and
20 presents predominantly with cardiac involvement; we did not see this mutation in
21 our study. The Cav1.2, transmembrane segment 6 of domain I (Figure 6), can be
22 encoded by two mutually exclusive exons, 8 and 8A.³ The two phenotypes and the
23 presence or absence of syndactyly are thought to be the result of differential

1 expression of exons 8 / 8A, for instance exon 8 represents 80% of mRNAs in heart
2 and brain. It is possible that some patients with TS2 may be undiagnosed due to the
3 absence of syndactyly, and succumb early in life to malignant arrhythmias.

4

5 Three patients in our study with TS1 demonstrated the abovementioned missense
6 mutation (pGly406Arg) in exon 8A. The other two patients with TS2 (pGly406R
7 mutation / exon 8) did not demonstrate as severe a phenotype due to a mosaic
8 mutation. Mosaicism occurs as a result of genetically distinct populations in the
9 somatic and germline tissues with heterogeneous expression, which may not follow
10 Mendelian rules of inheritance.^{12, 13} With patient #5 and #6, the mutation was
11 demonstrated to be absent from both parents thus occurring as a *de novo, post-*
12 *zygotic* event, after fusion of oocyte and spermatozoon but before cleavage of the
13 zygote into monozygotic twin embryos. There are only two other published reports
14 of mosaicism in TS, and these have described siblings with a more severe phenotype
15 inherited from a phenotypically normal parent with a mosaic mutation.^{3, 12} The
16 presence of mosaic mutations underlies the importance of testing tissues other than
17 peripheral lymphocytes: for instance, buccal swabs in parents of index cases. This
18 has important implications in counseling for future pregnancies.

19

20 Mutations affecting the Cav1.2 channel have wide-reaching consequences. In
21 addition to the electrical abnormalities, the presence of syndactyly, immune
22 deficiency, seizures, congenital heart defects, cognitive abnormalities, learning
23 difficulties and hypoglycemia underlie how different organ systems can be affected.

1 With respect to the developing brain, L-type calcium channels are essential for
2 linking electrical events to the activation of signaling pathways that regulate the
3 development and function of neurons.¹⁴ Krey et al demonstrated that the impaired
4 inactivation of the L-type calcium causes dendrite retraction when neurons are
5 stimulated electrically. The mechanism of action however is thought to be
6 independent of calcium influx into the cell; rather, it may be due to a conformational
7 change in the last transmembrane spanning region of the first repeat of Cav1.2,
8 controlling Gem and RhoA signaling cascades.¹⁵ This provides an insight into how
9 mutations in the *CACNA1C* gene might cause autistic traits and some of the other
10 neurological abnormalities in this condition. One of our patients had documented
11 recurrent hypoglycemia, although he was not hypoglycemic at the time of his
12 cardiac arrest (patient #2). The mechanism of hypoglycemia likely relates to the
13 effect of activation of L-type voltage-dependent calcium channels on the B-cells of
14 the pancreas.¹⁶ It is possible that some of the unsuccessful resuscitations in this
15 study may have been related to hypoglycemia. It was not known that the patient
16 who died during syndactyly surgery had a prolonged QT interval until reviewed
17 retrospectively. It is not usual practice for patients undergoing minor procedures to
18 have a preoperative ECG. This underlies the importance for specialists dealing with
19 syndactyly to be aware of this very rare condition, to obtain specialist input, and to
20 have the procedure performed in a specialist centre.

21

22 With respect to inactivation of calcium channels, it is thought that loss of voltage
23 dependent inactivation is the predominant effect in TS.^{3,4,6} Recent studies however

1 have suggested that Ca²⁺ / Calmodulin dependent inactivation (CDI) also plays an
2 important role: Dick et al have shown how the mutations p.Gly402Ser and
3 p.Gly406Arg have different effects on CDI; also they showed a non-linear effect of TS
4 gene expression on arrhythmia inducibility.¹⁷ This may explain why mosaic patients,
5 such as the two seen in our study, have a comparatively milder phenotype. In terms
6 of therapeutics it also means that we may not need to block all of the mutant TS
7 channels to prevent arrhythmogenesis. There are 2 reported cases where verapamil
8 has been used to treat TS. Jacobs report a reduction in the burden of ventricular
9 tachycardia in a TS2 patient with the mutation Gly402Ser.⁷ In another patient with
10 TS1 due to a mosaic p.Gly406Arg mutation, verapamil actually increased the
11 arrhythmia burden.¹² This illustrates how the same medication may produce
12 different effects depending on the mutation and its level of expression. All of the
13 surviving patients in our study were managed in the longer term with β -blockers. As
14 a newborn, patient #1 demonstrated lengthening of the QT interval with
15 intravenous propranolol, thus perpetuating 2:1 block. This paradoxical QT
16 prolongation with β -blocker administration has been seen in other studies and the
17 cause remains unclear.¹⁸ Isoproterenol seemed to alleviate 2:1 block, however the
18 improvement was intermittent and ultimately pacing was required. It does seem
19 counterintuitive that most patients with TS are managed chronically with β -
20 blockers given their effect on the newborn QT interval.¹⁸ Mexiletine resulted in
21 shortening of the QT interval in patient #1, which has been seen in other studies.¹⁸
22 ¹⁹ Mexiletine works by inhibition of the late inward sodium channel current without
23 having an effect on the inward calcium current.¹⁸ This current plays a role in the

1 rate adaptation of ventricular repolarization. Inhibition of this current results in a
2 blunted bradycardia dependent QT prolongation.¹⁸

3

4 The presence of 2:1 block as a neonate usually indicates that early pacemaker
5 placement will be required. The benefit of a pacemaker is two-fold; firstly, it
6 improves cardiac output by preventing 2:1 block. Secondly, it prevents heart rate
7 dependent variation of the QT interval.¹⁸ Whether it is performed endocardial or
8 epicardial will depend on the patients weight and institutional practice. The benefit
9 from pacing will usually outweigh any possible morbidity from the procedure once a
10 baby has reached around 2.5 kg. Defibrillator placement at a young age will usually
11 require a much higher burden of proof that there will be definite benefit. There is a
12 high risk of device malfunction and inappropriate shocks at this age using an
13 epicardial approach.²⁰ It is also possible that defibrillation in some cases may be
14 ineffective; two patients in our study died in hospital despite appropriate external
15 defibrillation. Another patient (patient #1) had a cardiac arrest which was judged
16 not to require cardioversion by an AED; this has also been reported in other
17 patients.²¹ Current recommendations are that an ICD may be considered in high-risk
18 patients such as those with TS without symptoms.²² Hypoglycemia is common in
19 patients with TS and this may account for some cardiac arrests, however this was
20 not definitely deemed to be a causative factor in any cases in our study. Bradycardia
21 and asystole, despite presence of a pacemaker, was seen in two patients in our
22 study. Two patients underwent defibrillator placement at 5 years of age, and both
23 have received at least one appropriate shock. As patients get older the morbidity

- 1 from defibrillators decreases, so implantation for primary prevention may be
- 2 appropriate.

1 Conclusions

2 This is a multicenter study looking at all cases of TS patients in the United Kingdom
3 over a 24-year period. If untreated, the mortality is high; however, with appropriate
4 medical and device therapy, longer-term survival is possible. Due to the multiple
5 systems affected by this disorder, not all deaths are related to tachyarrhythmias;
6 hence, careful consideration must be given prior to implanting defibrillators in
7 smaller patients.

8

9

Table 1. Baseline demographics

Patient	Age [#]	Gestation	Pregnancy	Delivery	Gender	2:1 HB	QTc * (msec)	Syndactyly	Seizures	Other diagnosis
1	1 day	28/40	Normal	EmLSCS	F	Yes	569	Yes	Yes	PDA
2	1 day	30/40	Heart Block	Normal	M	Yes	600	Yes	Yes	PDA, VSD
3	1 year	Term	Normal	Normal	F	No	NA	Yes	No	PDA
4	13 mths	Term	Normal	Normal	M	No	NA	Yes	No	PDA, EFE, RCA bridge
5	1 week	32/40	Twin	LSCS	M	Yes	554	No	No	Inguinal Hernia
6	1 day	32/40	Twin	LSCS	M	Yes	555	No	No	Pulmonary atresia

[#]Age at presentation, *Rate corrected QT (QTc) interval at time of diagnosis (Bazett's correction), HB: heart block, LSCS: lower segment caesarian section, PDA: patent ductus arteriosus, VSD: ventricular septal defect, EFE: endocardial fibroelastosis, RCA: right coronary artery

Table 2. Pacemaker and Defibrillator device information

Patient	Alive	Current Device	Current Age (years)	Age at first Device	Appropriate ICD shocks	Cardiac Arrest
1	Yes	PPM	1 yr, 7 mths	PPM @ 8 wks	NA	VF (related to anesthetic), Bradycardic arrest
2	No	NA	-	PPM @ 2 years	NA	Asystolic arrest on cardiology ward
3	Yes	ICD	24	ICD @ 5 years	Yes	Multiple appropriate shocks
4	No	NA	-	None	NA	torsade de pointes, not resuscitatable
5	Yes	ICD	7	ICD @ 5 years	Yes	Multiple appropriate shocks
6	Yes	PPM	7	PPM @ 4 years	NA	None

PPM: permanent pacemaker, ICD: Internal Cardiac Defibrillator,




Figure 1: Patient #1 at 2 days of age. There is marked prolongation of the QT and QTc intervals causing 2:1 block. Intravenous propranolol up to 0.3 mg/kg is administered and the QT interval increases, with no change to the 2:1 block.

Figure 2




Figure 2: This ECG demonstrates a prolonged QT interval with 2:1 block causing a resultant bradycardia.

Figure 3




Figure 3. Sanger sequence traces showing the G to A nucleotide substitution at position c.1216 in the proband. The G to A nucleotide substitution is not detected in the traces from the mother or fathers samples, which suggests a *de novo* occurrence.

Figure 4




Figure 4: Electropherogram showing normal sequence of the end of exon 8 of the *CACN1A* gene from a control DNA sample (trace A) and DNA extracted from buccal epithelial cells from patient #5 (trace B). At base position 1216 in trace B there are two peaks, corresponding to the normal allele of the gene (G) and the mutant allele (A). In an heterozygous individual, the normal allele and mutant allele are both equally represented and the coloured peaks overlap. The marked difference in height of these peaks in trace B is consistent with the mutant allele being present at a lower level than the normal allele, indicating somatic mosaicism in buccal epithelial cells.

Figure 5



Figure 5 shows the prolonged QT interval in patient #5. On the right is the tracing from the loop recorder demonstrating torsade de pointes. An ICD was subsequently implanted.

Figure 6




Figure 6 shows the Cav1.2 calcium channel. The most commonly seen mutation (G406R) was the known mutation in 5 out of 6 patients in our study. It is missense mutation in the transmembrane segment S6 of domain 1.

References

- [1] Napolitano C, Splawski I, Timothy KW, Bloise R, Priori SG. Timothy Syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., eds. *GeneReviews(R)*. Seattle (WA) 1993.
- [2] Erxleben C, Liao Y, Gentile S, Chin D, Gomez-Alegria C, Mori Y, et al. Cyclosporin and Timothy syndrome increase mode 2 gating of CaV1.2 calcium channels through aberrant phosphorylation of S6 helices. *Proceedings of the National Academy of Sciences of the United States of America* 2006; **103**: 3932-3937.
- [3] Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. *Proceedings of the National Academy of Sciences of the United States of America* 2005; **102**: 8089-8096; discussion 8086-8088.
- [4] Boczek NJ, Miller EM, Ye D, Nesterenko VV, Tester DJ, Antzelevitch C, et al. Novel Timothy syndrome mutation leading to increase in CACNA1C window current. *Heart rhythm : the official journal of the Heart Rhythm Society* 2015; **12**: 211-219.
- [5] Benitah JP, Alvarez JL, Gomez AM. L-type Ca(2+) current in ventricular cardiomyocytes. *Journal of molecular and cellular cardiology* 2010; **48**: 26-36.
- [6] Yarotsky V, Gao G, Peterson BZ, Elmslie KS. The Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation. *The Journal of physiology* 2009; **587**: 551-565.
- [7] Jacobs A, Knight BP, McDonald KT, Burke MC. Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8). *Heart rhythm : the official journal of the Heart Rhythm Society* 2006; **3**: 967-970.
- [8] Marks ML, Trippel DL, Keating MT. Long QT syndrome associated with syndactyly identified in females. *The American journal of cardiology* 1995; **76**: 744-745.
- [9] An HS, Choi EY, Kwon BS, Kim GB, Bae EJ, Noh CI, et al. Sudden cardiac arrest during anesthesia in a 30-month-old boy with syndactyly: a case of genetically proven Timothy syndrome. *Journal of Korean medical science* 2013; **28**: 788-791.
- [10] 2011 Census: Population Estimates for the United Kingdom, 27 March 2011.
- [11] Sicouri S, Timothy KW, Zygmunt AC, Glass A, Goodrow RJ, Belardinelli L, et al. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. *Heart rhythm : the official journal of the Heart Rhythm Society* 2007; **4**: 638-647.
- [12] Etheridge SP, Bowles NE, Arrington CB, Pilcher T, Rope A, Wilde AA, et al. Somatic mosaicism contributes to phenotypic variation in Timothy syndrome. *American journal of medical genetics Part A* 2011; **155A**: 2578-2583.
- [13] Youssoufian H, Pyeritz RE. Mechanisms and consequences of somatic mosaicism in humans. *Nature reviews Genetics* 2002; **3**: 748-758.
- [14] Dolmetsch R. Excitation-transcription coupling: signaling by ion channels to the nucleus. *Science's STKE : signal transduction knowledge environment* 2003; **2003**: PE4.
- [15] Krey JF, Pasca SP, Shcheglovitov A, Yazawa M, Schwemberger R, Rasmusson R, et al. Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. *Nature neuroscience* 2013; **16**: 201-209.

- [16] Bito M, Tomita T, Komori M, Taogoshi T, Kimura Y, Kihira K. The mechanisms of insulin secretion and calcium signaling in pancreatic beta-cells exposed to fluoroquinolones. *Biological & pharmaceutical bulletin* 2013; **36**: 31-35.
- [17] Dick IE, Joshi-Mukherjee R, Yang W, Yue DT. Arrhythmogenesis in Timothy Syndrome is associated with defects in Ca(2+)-dependent inactivation. *Nature communications* 2016; **7**: 10370.
- [18] Gao Y, Xue X, Hu D, Liu W, Yuan Y, Sun H, et al. Inhibition of late sodium current by mexiletine: a novel pharmaceutical approach in timothy syndrome. *Circulation Arrhythmia and electrophysiology* 2013; **6**: 614-622.
- [19] Krause U, Gravenhorst V, Kriebel T, Ruschewski W, Paul T. A rare association of long QT syndrome and syndactyly: Timothy syndrome (LQT 8). *Clinical research in cardiology : official journal of the German Cardiac Society* 2011; **100**: 1123-1127.
- [20] Stephenson EA, Batra AS, Knilans TK, Gow RM, Gradaus R, Balaji S, et al. A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population. *Journal of cardiovascular electrophysiology* 2006; **17**: 41-46.
- [21] Philipp LR, Rodriguez FH, 3rd. Cardiac arrest refractory to standard intervention in atypical Timothy syndrome (LQT8 type 2). *Proceedings* 2016; **29**: 160-162.
- [22] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology]. *Giornale italiano di cardiologia* 2016; **17**: 108-170.